Clinical Trials
3 trialsNCT05625399 2026-06-03
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05912244 2026-06-01
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting